Aeglea BioTherapeutics Interest Expense 2011-2026 | AGLE

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Aeglea BioTherapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
29.5 M	-20.7 M	-19.1 M	-7 K	-122 K	-5 K	-63 K	-57 K	-42 K	-36 K	-2 K	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
29.5 M	-20.7 M	-974 K

Quarterly Interest Expense Aeglea BioTherapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
40.3 M	-656 K	2.29 M	-	-18.8 M	-610 K	-483 K	-	2.34 M	-8 K	-72 K	-	24 K	5 K	-30 K	-	-24 K	-52 K	-31 K	-	2 K	-19 K	-6 K	-	-12 K	-16 K	-17 K	-	-13 K	-7 K	-17 K	-	-12 K	-12 K	-11 K	-	-9 K	-9 K	-6 K	-	-1 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
40.3 M	-18.8 M	776 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Aileron Therapeutics ALRN	685 K	-	10.36 %	$ 9.8 M	USA
Altimmune ALT	-190 K	$ 3.44	2.99 %	$ 303 M	USA
Ascendis Pharma A/S ASND	80.6 M	$ 218.06	-1.72 %	$ 5 B	Danmark
Amphastar Pharmaceuticals AMPH	23 K	$ 19.23	-1.38 %	$ 899 M	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Amarin Corporation plc AMRN	7 K	$ 14.6	0.76 %	$ 6.06 B	Irlanda
AgeX Therapeutics AGE	4.9 M	-	-10.17 %	$ 12.2 K	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Inventiva S.A. IVA	12.2 M	$ 6.08	5.19 %	$ 138 M	France
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	9.29 M	$ 1.4	2.19 %	$ 357 M	Britain
ChemoCentryx CCXI	2.7 M	-	-	$ 3.74 B	USA
Aytu BioScience AYTU	-512 K	$ 2.63	0.77 %	$ 16.5 M	USA
Atreca BCEL	3 K	-	-11.76 %	$ 5.79 M	USA
BioDelivery Sciences International BDSI	-6 K	-	-4.8 %	$ 255 M	USA
BeiGene, Ltd. BGNE	-42.6 M	-	0.49 %	$ 251 B	Cayman-islands
Benitec Biopharma BNTC	-126 K	$ 11.19	1.91 %	$ 461 M	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Arbutus Biopharma Corporation ABUS	459 K	$ 4.42	4.25 %	$ 734 M	Canada
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Allakos ALLK	8 K	-	-	$ 28.6 M	USA
Brickell Biotech BBI	5 K	-	-5.38 %	$ 6.06 M	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
Cabaletta Bio CABA	2 M	$ 2.82	-4.08 %	$ 3.29 M	USA
Calithera Biosciences CALA	2.65 M	-	-10.95 %	$ 876 K	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Cara Therapeutics CARA	3.59 M	-	-3.03 %	$ 260 M	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA